- White House Plans to Freeze Spending to Cut Deficit
- Week Ahead: Investors Go for Quality, Assess Recovery
- Hedge Fund Billionaire Paulson Reports New Citi Stake
- Cramer: 5 Earnings Reports to Watch Next Week
- Court Rejects 'Clawbacks' for Alleged Stanford Victims
- Cities With the Most Home Price Reductions
- Tax Credit Sparking First-Time Home Sales: Realtors
- Investors Cut Back US Stocks for Bigger Growth Abroad
- This Year's Biggest Thanksgiving Leftover: Cash
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- First Time Buyers Rescue Housing: Realtors
- Dollar General Trades Higher After Its IPO
- China: Low US interest rates threaten recovery
- Report: Swiss banks eye tax pledge for foreigners
- Rolls-Royce gets $2B engine orders for Airbus jets
- Zsa Zsa Gabor has $118,321 tax bill
- US Official: Climate agreement will take time
- Survey shows spike in 1st-time homebuyers
- Neb. meatpacker sued over handling of layoffs
- Dominica signs deal to export drinking water
- Hawaii's natural assets are being eaten up
NEW YORK - Medco Health Solutions Inc., the largest U.S. pharmacy benefits manager, is scheduled to report its third-quarter results Tuesday morning. The following is a summary of key developments and analyst commentary for the period.
OVERVIEW: Medco, of Franklin Lakes, N.J., makes money by designing benefits packages for plan sponsors and members. Profits have improved despite the recession because companies are looking for ways to cut their health care costs. Demand for low-cost generic drugs and mail order prescriptions, which are strongly profitable for Medco, has increased.
Strong sales of pricey specialty drugs has also helped Medco in recent quarters. The recession has affected demand for brand-name drugs, but pharmaceutical companies have gotten more aggressive in raising their prices of late, because many top-selling drugs will lose patent protection starting in 2011.
A year ago, the company earned 58 cents per share on revenue of $12.56 billion.
BY THE NUMBERS: Analysts polled by Thomson Reuters expect a profit of 72 cents per share and $14.68 billion in revenue.
ANALYST TAKE: Deutsche Bank analyst Ross Muken said he expects continued growth in generic sales, mail order prescription filling and specialty drug revenue.
"Medco remains the best organic growth story in the space," he wrote in a note to clients.
WHAT'S AHEAD: Three months ago, Medco raised its profit forecast to a range of $2.76 to $2.81 per share. Analysts currently expect $2.80 per share, on average.
The company said it will provide guidance for 2010, and analysts will be evaluating Medco's success at winning over new clients.
"The PBMs had a spectacular fiscal 2009 selling season, particularly for Medco, which had its best year for new business wins," Muken wrote. "This trend has continued into 2010, as more clients become convinced about the PBM value proposition." The analyst added that he does not think Medco or rival Express Scripts are facing too much pressure to cut prices.
STOCK PERFORMANCE: Medco shares jumped 21 percent during the third quarter, closing at $55.31. The stock set an annual high of $58.16 on Oct. 23 and closed at $56.12 Friday.
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
- Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
- The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
- Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
- A wealthy, distracted Texas driver crashed his million-dollar Bugatti Veyron sports car into a salt marsh, say police.









